Charles Schwab Investment Management Inc. Purchases 109,359 Shares of Bioventus Inc. (NYSE:BVS)

Charles Schwab Investment Management Inc. boosted its holdings in Bioventus Inc. (NYSE:BVS - Free Report) by 38.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 390,162 shares of the company's stock after acquiring an additional 109,359 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.48% of Bioventus worth $4,662,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in BVS. Royce & Associates LP bought a new stake in Bioventus during the third quarter worth about $8,337,000. Renaissance Technologies LLC increased its holdings in Bioventus by 401.5% during the 2nd quarter. Renaissance Technologies LLC now owns 503,175 shares of the company's stock valued at $2,893,000 after purchasing an additional 402,841 shares in the last quarter. Segall Bryant & Hamill LLC bought a new position in Bioventus in the 3rd quarter valued at $4,515,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Bioventus in the 3rd quarter valued at $3,092,000. Finally, Los Angeles Capital Management LLC acquired a new position in Bioventus in the third quarter worth $1,714,000. Institutional investors and hedge funds own 62.94% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on BVS shares. Canaccord Genuity Group lifted their price target on Bioventus from $12.00 to $15.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Craig Hallum raised their price objective on shares of Bioventus from $12.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, September 27th.

Bioventus Trading Down 1.0 %

BVS traded down $0.11 during mid-day trading on Friday, reaching $11.03. The stock had a trading volume of 135,374 shares, compared to its average volume of 393,989. The firm's fifty day simple moving average is $12.08 and its two-hundred day simple moving average is $9.52. The stock has a market capitalization of $895.14 million, a P/E ratio of -18.08 and a beta of 0.79. Bioventus Inc. has a 52 week low of $3.90 and a 52 week high of $14.38. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41.

Bioventus (NYSE:BVS - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, hitting analysts' consensus estimates of $0.06. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. The firm had revenue of $138.96 million during the quarter, compared to analyst estimates of $132.57 million. During the same period last year, the company earned $0.05 earnings per share. On average, equities analysts predict that Bioventus Inc. will post 0.41 EPS for the current year.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.